Cellect Biotechnology Ltd

Quoin Pharmaceuticals Ltd. is a specialty pharmaceutical company engaged in the development of therapeutic products for the treatment of rare and orphan diseases. The company was founded on March 5, 2018 and is headquartered in Kefar Sava, Israel.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.

The stock price of Cellect Biotechnology Ltd (NASDAQ: APOP) has increased by over 75% pre-market. This is why it happened.

APOP Stock Price Increases Over 75% Pre-Market: Why It Happened

Up to $25 million of funding at $75 million pre-money valuation to be available to the combined company concurrently with the merger

Cellect Biotechnology and Quoin Pharmaceuticals Announce Strategic Merger

Promising Progress on Clinical D evelopment Progress , Collaboration s and Partnering

Cellect Biotechnology Reports Third Quarter Financial and Operating Results; Recent Developments Position Company to Accelerate Progress in 2021

Tel Aviv, Israel , Oct. 22, 2020 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology which enables the functional selection of cells facilitating safer and more efficacious cell and gene therapies, today announced that it has initiated its clinical trial in the U.S. to determine the safety and tolerability of the ApoGraft technology for bone marrow transplantations (BMT).  The trial will enroll 18 patients and the primary end point of the study is overall incidence, frequency and severity of adverse events potentially related to ApoGraft at 180 and 360 days from transplantation.

Cellect Biotechnology Initiates U.S. Clinical Trial of ApoGraft

Management to Highlight Progress in Bone Marrow Transplant (BMT) and Chimeric Antigen Receptor T Cell (CAR T) Business Collaborations

Cellect Biotechnology to Present at the 2020 Cell & Gene Meeting on the Mesa

TEL AVIV, Israel, Aug. 12, 2020 /PRNewswire/ -- Cellect Biotechnology Ltd.

Cellect Biotechnology Reports Second Quarter Financial and Operating Results; First Half 2020 Strategic Developments Create Long-Term Revenue Catalysts

TEL AVIV, Israel, May 21, 2020 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today reported financial and operating results for the first quarter ended March 31, 2020 and provided an...

Cellect Biotechnology Reports First Quarter 2020 Financial and Operating Results; Continues to Demonstrate Significant Progress Despite Adjusted Operations Due to COVID-19

TEL AVIV, Israel, May  21, 2020  (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology which enables the functional selection of stem cells, today reported financial and operating results for the first quarter ended March 31, 2020 and provided an update on recent operating developments, including the status of the previously announced LOIs with Canndoc Ltd, a wholly owned subsidiary of publicly-traded Intercure Ltd. (TASE: INCR).

Cellect Biotechnology Reports  First Quarter 2020 Financial and Operating Results; Continues to Demonstrate Significant Progress Despite Adjusted Operations Due to COVID-19

TEL AVIV, Israel, May  12, 2020  (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced the agreement by several investors to exercise certain warrants issued in February 2019 to purchase up to an aggregate of 534,160,000 ordinary shares represented by 534,160 American Depositary Shares (ADSs) having an original exercise price of $7.50 per ADS,  at a reduced exercise price of $2.75 per ADSs. Simultaneously with entry into these agreements the Company determined to lower the exercise price of all outstanding warrants issued in February 2019 with an original exercise price of $7.50 to $2.75 per share. 

Cellect Biotechnology Announces Exercise of Warrants for Cash Proceeds of Approximately $1.5 Million

Cellect Biotechnology Ltd. (NASDAQ: APOP) shares nearly doubled to start the week after the company announced progress with its bone marrow transplantation process.

Why Cellect Biotech’s Bone Marrow Transplantation Update Is Huge

Shares of thinly-traded nano-cap biotech Cellect Biotechnology Ltd – ADR (NASDAQ: APOP) are advancing strongly Wednesday.

Nano-Cap Cellect Biotechnology Rips Higher On Medical Cannabis Deal

Cellect Biotechnology (APOP) news for Tuesday includes new patent approvals overseas that have APOP stock soaring higher.
The post Cellect Biotechnology News: APOP Stock Rockets 76% on New Patent Approvals appeared first on InvestorPlace.

Cellect Biotechnology News: APOP Stock Rockets 76% on New Patent Approvals

Cellect Biotechnology Ltd – ADR (NASDAQ: APOP) shares are more than doubling following an announcement concerning patents in two regions.

Cellect Biotech Shares Rip On Intention To Award Stem Cell-related Patents In Europe, Israel

The thinly traded nano-cap penny stock CELLECT BIOTECH/S ADR (NASDAQ: APOP) was soaring Monday.

News for Cellect Biotechnology Ltd Stock (APOP)